Net Worth Advisory Group Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Net Worth Advisory Group purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) during the third quarter, Holdings Channel.com reports. The firm purchased 1,092 shares of the medical research company’s stock, valued at approximately $259,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jennison Associates LLC raised its holdings in shares of IQVIA by 7.3% during the first quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock valued at $35,636,000 after acquiring an additional 9,578 shares during the period. PGGM Investments lifted its holdings in shares of IQVIA by 55.8% in the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after purchasing an additional 4,326 shares in the last quarter. Fiduciary Alliance LLC acquired a new stake in shares of IQVIA in the first quarter worth $1,864,000. SG Americas Securities LLC grew its holdings in shares of IQVIA by 80.1% during the first quarter. SG Americas Securities LLC now owns 45,787 shares of the medical research company’s stock valued at $11,579,000 after buying an additional 20,369 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new position in IQVIA during the first quarter valued at $3,365,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

Shares of IQV opened at $236.69 on Monday. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The company’s fifty day moving average price is $239.08 and its 200 day moving average price is $231.08. The company has a market capitalization of $43.15 billion, a PE ratio of 30.74, a price-to-earnings-growth ratio of 2.22 and a beta of 1.49.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm’s revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.22 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Barclays reduced their price target on shares of IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research report on Tuesday, October 15th. Jefferies Financial Group lowered shares of IQVIA from a “buy” rating to a “hold” rating and decreased their target price for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. UBS Group boosted their price target on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Morgan Stanley lifted their price objective on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, July 23rd. Finally, Evercore ISI dropped their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $267.87.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.